While its customers are losing weight, Novo Nordisk, the creator of the mega-hit drug Ozempic, is shedding loads of market ...

However, the late-stage study results fell short of Novo Nordisk ’s injectable Wegovy, which delivered 14.9 per cent weight ...

Some studies have linked the popular weight-loss drugs with a potentially higher risk of eye problems and vision loss. Should ...

Otte took on the title in February, the culmination of nearly 25 years spent with the Danish drugmaker. As of his departure ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Mounjaro manufacturer Eli Lilly has unveiled the test results of its new oral GLP-1 medication, orforglipron. The obesity pill, which is designed to be taken daily by patients who are severely ...

Indian pharmaceutical companies are preparing for weighty gains when the patent for semaglutide, the active pharmaceutical ...

Trials of a daily obesity pill have shown it can help patients lose around 12% of their body weight over 72 weeks. The ...

GLP-1 receptor agonists are associated with risk reductions for dozens of diseases and conditions in addition to rapid weight ...

An experimental once-daily pill to treat obesity can help people lose a significant amount of weight, according to new data ...

LLY's stock drops despite Q2 earnings beat, as its oral obesity pill underwhelms with 12.4% weight loss in trial.